GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Cyclically Adjusted Price-to-FCF

Grifols (XMAD:GRF) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Grifols Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Grifols Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Grifols's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Cyclically Adjusted Price-to-FCF Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.14 42.21 - - -

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Grifols's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Grifols's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Grifols's Cyclically Adjusted Price-to-FCF falls into.



Grifols Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Grifols's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Grifols's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/121.2698*121.2698
=0.000

Current CPI (Dec. 2023) = 121.2698.

Grifols Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 0.222 100.994 0.267
201309 0.054 100.597 0.065
201312 0.247 101.306 0.296
201403 0.108 100.139 0.131
201406 0.264 101.081 0.317
201409 0.275 100.441 0.332
201412 0.355 100.251 0.429
201503 -0.473 99.474 -0.577
201506 0.604 101.138 0.724
201509 -0.243 99.559 -0.296
201512 0.351 100.268 0.425
201603 -0.006 98.638 -0.007
201606 0.065 100.333 0.079
201609 0.195 99.737 0.237
201612 0.129 101.842 0.154
201703 0.116 100.896 0.139
201706 0.224 101.848 0.267
201709 0.180 101.524 0.215
201712 0.234 102.975 0.276
201803 0.049 102.122 0.058
201806 0.126 104.165 0.147
201809 0.128 103.818 0.150
201812 0.319 104.193 0.371
201903 -0.370 103.488 -0.434
201906 0.309 104.612 0.358
201909 0.177 103.905 0.207
201912 0.104 105.015 0.120
202003 0.028 103.469 0.033
202006 0.531 104.254 0.618
202009 0.340 103.521 0.398
202012 0.226 104.456 0.262
202103 0.173 104.857 0.200
202106 0.130 107.102 0.147
202112 0.000 111.298 0.000
202206 0.000 118.044 0.000
202209 0.000 117.221 0.000
202212 0.000 117.650 0.000
202306 0.000 120.278 0.000
202309 0.000 121.343 0.000
202312 0.000 121.270 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Grifols  (XMAD:GRF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Grifols Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Grifols's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (XMAD:GRF) Business Description

Industry
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.